Milestone Pharmaceuticals Expands CARDAMYST Coverage as AFib-RVR Trial Advances
Event summary
- Over 50% of commercially insured lives in the U.S. now have coverage for CARDAMYST® (etripamil) nasal spray, up from 25% in Q2.
- Phase 3 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR) has activated first clinical sites.
- $170.6 million in cash reserves as of June 30, 2026, providing runway into H2 2027.
- More than 800 unique prescribers have started patients on CARDAMYST through June 30, 2026.
The big picture
Milestone Pharmaceuticals is making strategic progress in expanding the reach of CARDAMYST, a novel treatment for paroxysmal supraventricular tachycardia (PSVT). The significant increase in insurance coverage and the initiation of the Phase 3 trial for AFib-RVR position the company to tap into larger patient populations. However, sustaining commercial momentum and managing financial resources will be critical as it navigates regulatory pathways and market dynamics.
What we're watching
- Commercial Momentum
- Whether the recent increase in insurance coverage will accelerate CARDAMYST prescriptions and drive revenue growth.
- Regulatory Pathway
- The pace at which the Phase 3 AFib-RVR trial progresses and whether it meets regulatory milestones for a supplemental New Drug Application (sNDA).
- Financial Runway
- How Milestone Pharmaceuticals manages its cash reserves to sustain operations into H2 2027 amid increasing commercialization costs.